Current Edition


As Congress weighs drug price restraints, ICER calls out ‘unsupported’ increases

Congress is considering legislation that could force drugmakers to pay steep rebates to Medicare for patent-protected drugs that have price increases exceeding inflation, as well …

Continue Reading →

PhRMA criticizes ICER in latest skirmish over valuing drugs

Industry lobbying group PhRMA on Thursday warned the use of cost-effectiveness estimates like those developed by the Institute for Clinical and Economic Review could force …

Continue Reading →